158 related articles for article (PubMed ID: 36682367)
21. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
Pearson ADJ; Rossig C; Lesa G; Diede SJ; Weiner S; Anderson J; Gray J; Geoerger B; Minard-Colin V; Marshall LV; Smith M; Sondel P; Bajars M; Baldazzi C; Barry E; Blackman S; Blanc P; Capdeville R; Caron H; Cole PD; Jiménez JC; Demolis P; Donoghue M; Elgadi M; Gajewski T; Galluzzo S; Ilaria R; Jenkner A; Karres D; Kieran M; Ligas F; Lowy I; Meyers M; Oprea C; Peddareddigari VGR; Sterba J; Stockman PK; Suenaert P; Tabori U; van Tilburg C; Yancey T; Weigel B; Norga K; Reaman G; Vassal G
Eur J Cancer; 2020 Mar; 127():52-66. PubMed ID: 31986450
[TBL] [Abstract][Full Text] [Related]
22. The European Regulation on medicines for paediatric use.
Dunne J
Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
[TBL] [Abstract][Full Text] [Related]
23. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.
Ceci A; Felisi M; Baiardi P; Bonifazi F; Catapano M; Giaquinto C; Nicolosi A; Sturkenboom M; Neubert A; Wong I
Eur J Clin Pharmacol; 2006 Nov; 62(11):947-52. PubMed ID: 17021892
[TBL] [Abstract][Full Text] [Related]
24. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
25. New Information on Old Medicinal Products: A Cross-Sectional Analysis of Guidance for Paediatric Use for Substances on the European Priority List of Off-Patent Medicinal Products.
Mogensen AB; Christiansen H; De Bruin ML; Hallgreen CE
Paediatr Drugs; 2022 Nov; 24(6):679-687. PubMed ID: 35962257
[TBL] [Abstract][Full Text] [Related]
26. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
27. Does the EU's Paediatric Regulation work for new medicines for children in Denmark, Finland, Norway and Sweden? A cross-sectional study.
Lepola P; Wang S; Tötterman AM; Gullberg N; Harboe KM; Kimland E
BMJ Paediatr Open; 2020; 4(1):e000880. PubMed ID: 33437879
[TBL] [Abstract][Full Text] [Related]
28. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
Rose K; Senn S
Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
[TBL] [Abstract][Full Text] [Related]
29. Ophthalmic medicine regulatory approvals through the European Centralised Procedure, 1999-2017: Clinical efficacy considerations.
Morgan-Warren PJ
Eur J Ophthalmol; 2020 Mar; 30(2):321-349. PubMed ID: 30832499
[TBL] [Abstract][Full Text] [Related]
30. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
Ferrario A
Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
[TBL] [Abstract][Full Text] [Related]
31. Public health relevance of medicines developed under paediatric legislation in Europe and the USA: a systematic mapping study.
Volodina A; Jahn A; Jahn R
BMJ Paediatr Open; 2024 Apr; 8(1):. PubMed ID: 38569742
[TBL] [Abstract][Full Text] [Related]
32. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use.
Impicciatore P; Choonara I
Br J Clin Pharmacol; 1999 Jul; 48(1):15-8. PubMed ID: 10383554
[TBL] [Abstract][Full Text] [Related]
33. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
34. Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.
Brinkhuis F; Goettsch WG; Mantel-Teeuwisse AK; Bloem LT
BMJ; 2024 Feb; 384():e077391. PubMed ID: 38418086
[TBL] [Abstract][Full Text] [Related]
35. Is the European pediatric medicine regulation working for children and adolescents with cancer?
Vassal G; Geoerger B; Morland B
Clin Cancer Res; 2013 Mar; 19(6):1315-25. PubMed ID: 23329813
[TBL] [Abstract][Full Text] [Related]
36. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ; Zwaan CM; Kolb EA; Karres D; Guillot J; Kim SY; Marshall L; Tasian SK; Smith M; Cooper T; Adamson PC; Barry E; Benettaib B; Binlich F; Borgman A; Brivio E; Capdeville R; Delgado D; Faller D; Fogelstrand L; Fraenkel PG; Hasle H; Heenen D; Kaspers G; Kieran M; Klusmann JH; Lesa G; Ligas F; Mappa S; Mohamed H; Moore A; Morris J; Nottage K; Reinhardt D; Scobie N; Simko S; Winkler T; Norga K; Reaman G; Vassal G
Eur J Cancer; 2020 Sep; 136():116-129. PubMed ID: 32688206
[TBL] [Abstract][Full Text] [Related]
37. Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?
Cramer A; Sørup FKH; Christensen HR; Petersen TS; Karstoft K
Lancet Oncol; 2023 Sep; 24(9):e385-e394. PubMed ID: 37657479
[TBL] [Abstract][Full Text] [Related]
38. [Improving drug licensing for children and adolescents : Position paper from the More Medicines for Minors Symposion 8 June 2015 in Bonn].
Riedel C; Lehmann B; Broich K; Sudhop T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2016 Dec; 59(12):1587-1592. PubMed ID: 27778087
[TBL] [Abstract][Full Text] [Related]
39. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.
Pearson ADJ; Scobie N; Norga K; Ligas F; Chiodin D; Burke A; Minard-Colin V; Adamson P; Marshall LV; Balakumaran A; Benettaib B; Bhargava P; Bollard CM; Bolotin E; Bomken S; Buechner J; Burkhardt B; Caron H; Copland C; Demolis P; Egorov A; Farhan M; Zugmaier G; Gross T; Horton-Taylor D; Klapper W; Lesa G; Marcus R; Miles RR; Nottage K; Pacaud L; Ricafort R; Schrappe M; Sterba J; Vezan R; Weiner S; Kim SY; Reaman G; Vassal G
Eur J Cancer; 2019 Mar; 110():74-85. PubMed ID: 30772656
[TBL] [Abstract][Full Text] [Related]
40. Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation.
Kalland ME; Pose-Boirazian T; Palomo GM; Naumann-Winter F; Costa E; Matusevicius D; Duarte DM; Malikova E; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
Gene Ther; 2024 Mar; ():. PubMed ID: 38480914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
